Lexington, MA, United States of America

Christopher C Fraser

USPTO Granted Patents = 26 

 

 

Average Co-Inventor Count = 1.8

ph-index = 11

Forward Citations = 357(Granted Patents)


Location History:

  • Lexington, MA (US) (2003 - 2012)
  • Arlington, MA (US) (2013 - 2023)

Company Filing History:


Years Active: 2003-2023

Loading Chart...
Loading Chart...
Loading Chart...
26 patents (USPTO):Explore Patents

Title: Christopher C. Fraser: Innovator in Allergy Therapy

Introduction

Christopher C. Fraser, based in Lexington, MA, is an accomplished inventor known for his significant contributions to the field of allergy therapy. With a remarkable portfolio of 26 patents, Fraser's work focuses on developing innovative synthetic nanocarrier technologies aimed at improving immune responses related to allergies.

Latest Patents

Fraser's latest patents showcase his dedication to advancing allergy treatments. One of his noteworthy inventions, titled "Tolerogenic Synthetic Nanocarriers for Allergy Therapy," discloses synthetic nanocarrier compositions that include immunosuppressants and MHC Class II-restricted epitopes of allergens. These compositions are designed to induce tolerogenic immune responses specific to allergens, offering a potential breakthrough in allergy management. Additionally, he developed another patent, "Tolerogenic Synthetic Nanocarriers," which describes compositions that incorporate synthetic nanocarriers and immunosuppressants, leading to immune suppressive effects. Some of these compositions can also include antigen, enabling antigen-specific tolerogenic immune responses.

Career Highlights

Throughout his career, Christopher C. Fraser has had the opportunity to work with notable companies in the biotechnology sector. He has significantly contributed to Millennium Pharmaceuticals Limited and Selecta Biosciences, Inc., where he applied his innovative ideas to develop therapeutic solutions.

Collaborations

Fraser's journey has been marked by fruitful collaborations with esteemed colleagues, including Roberto A. Maldonado and Takashi Kei Kishimoto. Their joint efforts have furthered the exploration of synthetic nanocarrier technologies, driving advancements in allergy therapies.

Conclusion

In conclusion, Christopher C. Fraser's innovative work and dedication to developing synthetic nanocarrier technologies represent a significant stride forward in allergy therapy. His extensive patent portfolio and professional collaborations underscore his influence in the field, making him a respected figure in the innovation and invention landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…